IRIS: Difference between revisions
Jump to navigation
Jump to search
| Line 255: | Line 255: | ||
p-Chlorophenyl methyl sulfone||Not Assessed under the IRIS program.|||||| | p-Chlorophenyl methyl sulfone||Not Assessed under the IRIS program.|||||| | ||
p-Chlorophenyl methyl sulfoxide||Not Assessed under the IRIS program.|||||| | p-Chlorophenyl methyl sulfoxide||Not Assessed under the IRIS program.|||||| | ||
Chloroprene|| | Chloroprene|126-99-8|Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively|mg /m<sup>3</sup>|2x10<sup>-2</sup>|BMDL (HEC)|2|Medium/High|1021 | ||
Chlorothalonil||Not Assessed under the IRIS program.|||||| | Chlorothalonil||Not Assessed under the IRIS program.|||||| | ||
o-Chlorotoluene||Not Assessed under the IRIS program.|||||| | o-Chlorotoluene||Not Assessed under the IRIS program.|||||| | ||
| Line 261: | Line 261: | ||
Chlorpyrifos||Not Assessed under the IRIS program.|||||| | Chlorpyrifos||Not Assessed under the IRIS program.|||||| | ||
Chlorsulfuron||Not Assessed under the IRIS program.|||||| | Chlorsulfuron||Not Assessed under the IRIS program.|||||| | ||
Chromium(III), insoluble salts|| | Chromium(III), insoluble salts|16065-83-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0028 | ||
Chromium(VI)|| | Chromium(VI) (Chromic acid mists and dissolved Cr(VI) aerosols)|18540-29-9|Nasal septum atrophy|mg /m<sup>3</sup>|8x10<sup>-6</sup>|LOAEL (ADJ)|0.000714|Low|0144 | ||
Chromium(VI) (Cr(VI) particulates)|18540-29-9|Lactate dehydrogenase in bronchioalveolar lavage fluid||1x10<sup>-4</sup>|BMC<sub>10</sub> (ADJ)|0.034|Medium|0144 | |||
Chrysene||Not Assessed under the IRIS program.|||||| | Chrysene||Not Assessed under the IRIS program.|||||| | ||
Coke oven emissions||Not Assessed under the IRIS program.|||||| | Coke oven emissions||Not Assessed under the IRIS program.|||||| | ||
| Line 269: | Line 270: | ||
Creosote||Not Assessed under the IRIS program.|||||| | Creosote||Not Assessed under the IRIS program.|||||| | ||
Crotonaldehyde||Not Assessed under the IRIS program.|||||| | Crotonaldehyde||Not Assessed under the IRIS program.|||||| | ||
Cumene|| | Cumene|98-82-8|Increased kidney weights in female rats and adrenal weights in male and female rats|mg /m<sup>3</sup>|4x10<sup>-1</sup>|NOAEL (HEC)|435|Medium|0306 | ||
Cyanazine||Not Assessed under the IRIS program.|||||| | Cyanazine||Not Assessed under the IRIS program.|||||| | ||
Cyanide, free||Not Assessed under the IRIS program.|||||| | Cyanide, free||Not Assessed under the IRIS program.|||||| | ||
Cyanogen||Not Assessed under the IRIS program.|||||| | Cyanogen||Not Assessed under the IRIS program.|||||| | ||
Cyanogen bromide||Not Assessed under the IRIS program.|||||| | Cyanogen bromide||Not Assessed under the IRIS program.|||||| | ||
Cyclohexane|| | Cyclohexane|110-82-7|Reduced pup weights in the F1 and F2 generations|mg /m<sup>3</sup>|6|BMCL<sub>1sd</sub> (HEC)|1822|Low/Medium|1005 | ||
Cyclohexanone||Not Assessed under the IRIS program.|||||| | Cyclohexanone||Not Assessed under the IRIS program.|||||| | ||
Cyclohexylamine||Not Assessed under the IRIS program.|||||| | Cyclohexylamine||Not Assessed under the IRIS program.|||||| | ||
| Line 283: | Line 284: | ||
Dalapon, sodium salt||Not Assessed under the IRIS program.|||||| | Dalapon, sodium salt||Not Assessed under the IRIS program.|||||| | ||
Danitol||Not Assessed under the IRIS program.|||||| | Danitol||Not Assessed under the IRIS program.|||||| | ||
2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209)|| | 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209)|1163-19-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0035 | ||
Demeton||Not Assessed under the IRIS program.|||||| | Demeton||Not Assessed under the IRIS program.|||||| | ||
Di (2-ethylhexyl)phthalate (DEHP)||Not Assessed under the IRIS program.|||||| | Di (2-ethylhexyl)phthalate (DEHP)||Not Assessed under the IRIS program.|||||| | ||
Di(2-ethylhexyl)adipate||Not Assessed under the IRIS program.|||||| | Di(2-ethylhexyl)adipate||Not Assessed under the IRIS program.|||||| | ||
2,4-Diaminotoluene|| | 2,4-Diaminotoluene|95-80-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0536 | ||
Diazomethane|| | Diazomethane|334-88-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0616 | ||
Dibenz[a,h]anthracene||Not Assessed under the IRIS program.|||||| | Dibenz[a,h]anthracene||Not Assessed under the IRIS program.|||||| | ||
Dibenzofuran||Not Assessed under the IRIS program.|||||| | Dibenzofuran||Not Assessed under the IRIS program.|||||| | ||
1,2-Dibromo-3-chloropropane (DBCP)|| | 1,2-Dibromo-3-chloropropane (DBCP)|96-12-8|Testicular effects|mg /m<sup>3</sup>|2x10<sup>-4</sup>|NOAEL (HEC)|0.17|Medium|0414 | ||
1,4-Dibromobenzene||Not Assessed under the IRIS program.|||||| | 1,4-Dibromobenzene||Not Assessed under the IRIS program.|||||| | ||
Dibromochloromethane||Not Assessed under the IRIS program.|||||| | Dibromochloromethane||Not Assessed under the IRIS program.|||||| | ||
Dibromodichloromethane||Not Assessed under the IRIS program.|||||| | Dibromodichloromethane||Not Assessed under the IRIS program.|||||| | ||
p,p'-Dibromodiphenyl ether||Not Assessed under the IRIS program.|||||| | p,p'-Dibromodiphenyl ether||Not Assessed under the IRIS program.|||||| | ||
1,2-Dibromoethane|| | 1,2-Dibromoethane|106-93-4|Nasal inflammation|mg /m<sup>3</sup>|9x10<sup>-3</sup>|BMCL<sub>10</sub> (HEC)|2.8|Medium|0361 | ||
Dibutyl phthalate|| | Dibutyl phthalate|84-74-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0038 | ||
Dicamba||Not Assessed under the IRIS program.|||||| | Dicamba||Not Assessed under the IRIS program.|||||| | ||
Dichloroacetic acid|| | Dichloroacetic acid|79-43-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0654 | ||
1,3-Dichlorobenzene||Not Assessed under the IRIS program.|||||| | 1,3-Dichlorobenzene||Not Assessed under the IRIS program.|||||| | ||
1,4-Dichlorobenzene|| | 1,4-Dichlorobenzene|106-46-7|Increased liver weights in P1 males|mg /m<sup>3</sup>|8x10<sup>-1</sup>|NOAEL (HEC)|75|Medium|0552 | ||
1,2-Dichlorobenzene||Not Assessed under the IRIS program.|||||| | 1,2-Dichlorobenzene||Not Assessed under the IRIS program.|||||| | ||
3,3'-Dichlorobenzidine|| | 3,3'-Dichlorobenzidine|91-94-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0504 | ||
Dichlorodifluoromethane||Not Assessed under the IRIS program.|||||| | Dichlorodifluoromethane||Not Assessed under the IRIS program.|||||| | ||
p,p'-Dichlorodiphenyl dichloroethane (DDD)||Not Assessed under the IRIS program.|||||| | p,p'-Dichlorodiphenyl dichloroethane (DDD)||Not Assessed under the IRIS program.|||||| | ||
| Line 310: | Line 311: | ||
1,2-Dichloroethane||Not Assessed under the IRIS program.|||||| | 1,2-Dichloroethane||Not Assessed under the IRIS program.|||||| | ||
1,1-Dichloroethane||Not Assessed under the IRIS program.|||||| | 1,1-Dichloroethane||Not Assessed under the IRIS program.|||||| | ||
trans-1,2-Dichloroethylene|| | trans-1,2-Dichloroethylene|156-60-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0314 | ||
cis-1,2-Dichloroethylene|| | cis-1,2-Dichloroethylene|156-59-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0418 | ||
1,1-Dichloroethylene (1,1-DCE)|| | 1,1-Dichloroethylene (1,1-DCE)|75-35-4|Liver toxicity (fatty change)|mg /m<sup>3</sup>|2x10<sup>-1</sup>|BMCL<sub>10</sub> (HEC)|6.9|Medium|0039 | ||
Dichloromethane|| | Dichloromethane|75-09-2|Hepatic effects (hepatic vacuolation)|mg /m<sup>3</sup>|6x10<sup>-1</sup>|BMDL<sub>10</sub> (HEC)|17.2|Medium/High|0070 | ||
2,4-Dichlorophenol||Not Assessed under the IRIS program.|||||| | 2,4-Dichlorophenol||Not Assessed under the IRIS program.|||||| | ||
4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB)||Not Assessed under the IRIS program.|||||| | 4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB)||Not Assessed under the IRIS program.|||||| | ||
2,4-Dichlorophenoxyacetic acid (2,4-D)||Not Assessed under the IRIS program.|||||| | 2,4-Dichlorophenoxyacetic acid (2,4-D)||Not Assessed under the IRIS program.|||||| | ||
1,2-Dichloropropane|| | 1,2-Dichloropropane|78-87-5|Hyperplasia of the nasal mucosa|mg /m<sup>3</sup>|4x10<sup>-3</sup>|LOAEL (HEC)|1.3|Medium|0601 | ||
2,3-Dichloropropanol||Not Assessed under the IRIS program.|||||| | 2,3-Dichloropropanol||Not Assessed under the IRIS program.|||||| | ||
1,3-Dichloropropene|| | 1,3-Dichloropropene|542-75-6|Hypertrophy/ hyperplasia of the nasal respiratory epithelium|mg /m<sup>3</sup>|2x10<sup>-2</sup>|BMCL<sub>10</sub> (HEC)|0.72|High|0224 | ||
Dichlorvos|| | Dichlorvos|62-73-7|Decreased brain cholinesterase activity|mg /m<sup>3</sup>|5x10<sup>-4</sup>|NOAEL (HEC)|0.05|Medium|0151 | ||
Dicofol||Not Assessed under the IRIS program.|||||| | Dicofol||Not Assessed under the IRIS program.|||||| | ||
Dieldrin||Not Assessed under the IRIS program.|||||| | Dieldrin||Not Assessed under the IRIS program.|||||| | ||
Diesel engine exhaust|| | Diesel engine exhaust|NA|Pulmonary inflammation and histopathology|mg /m<sup>3</sup>|5x10<sup>-3</sup>|NOAEL (HEC)|0.144|Medium|0642 | ||
Diethyl phthalate||Not Assessed under the IRIS program.|||||| | Diethyl phthalate||Not Assessed under the IRIS program.|||||| | ||
Diethyl sulfate|| | Diethyl sulfate|64-67-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0615 | ||
Diethyl-p-nitrophenylphosphate||Not Assessed under the IRIS program.|||||| | Diethyl-p-nitrophenylphosphate||Not Assessed under the IRIS program.|||||| | ||
Diethylene glycol dinitrate (DEGDN)||Not Assessed under the IRIS program.|||||| | Diethylene glycol dinitrate (DEGDN)||Not Assessed under the IRIS program.|||||| | ||
Difenzoquat||Not Assessed under the IRIS program.|||||| | Difenzoquat||Not Assessed under the IRIS program.|||||| | ||
Diflubenzuron||Not Assessed under the IRIS program.|||||| | Diflubenzuron||Not Assessed under the IRIS program.|||||| | ||
1,1-Difluoroethane|| | 1,1-Difluoroethane|75-37-6|No adverse effects observed|mg /m<sup>3</sup>|4x10<sup>1</sup>|NOAEL (HEC)|12051|Medium|0665 | ||
Diisopropyl methylphosphonate (DIMP)||Not Assessed under the IRIS program.|||||| | Diisopropyl methylphosphonate (DIMP)||Not Assessed under the IRIS program.|||||| | ||
Dimethipin||Not Assessed under the IRIS program.|||||| | Dimethipin||Not Assessed under the IRIS program.|||||| | ||
Dimethoate||Not Assessed under the IRIS program.|||||| | Dimethoate||Not Assessed under the IRIS program.|||||| | ||
Dimethyl phthalate|| | Dimethyl phthalate|131-11-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0353 | ||
Dimethyl sulfate|| | Dimethyl sulfate|77-78-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0365 | ||
Dimethyl terephthalate (DMT)||Not Assessed under the IRIS program.|||||| | Dimethyl terephthalate (DMT)||Not Assessed under the IRIS program.|||||| | ||
Dimethylamine|| | Dimethylamine|124-40-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0228 | ||
N-N-Dimethylaniline||Not Assessed under the IRIS program.|||||| | N-N-Dimethylaniline||Not Assessed under the IRIS program.|||||| | ||
3,3-Dimethylbenzidine|| | 3,3-Dimethylbenzidine|119-93-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0538 | ||
N,N-Dimethylformamide|| | N,N-Dimethylformamide|68-12-2|Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities|mg /m<sup>3</sup>|3x10<sup>-2</sup>|LOAEL (HEC)|7.9|Medium|0511 | ||
3,4-Dimethylphenol||Not Assessed under the IRIS program.|||||| | 3,4-Dimethylphenol||Not Assessed under the IRIS program.|||||| | ||
2,6-Dimethylphenol||Not Assessed under the IRIS program.|||||| | 2,6-Dimethylphenol||Not Assessed under the IRIS program.|||||| | ||
| Line 347: | Line 348: | ||
m-Dinitrobenzene||Not Assessed under the IRIS program.|||||| | m-Dinitrobenzene||Not Assessed under the IRIS program.|||||| | ||
o-Dinitrobenzene||Not Assessed under the IRIS program.|||||| | o-Dinitrobenzene||Not Assessed under the IRIS program.|||||| | ||
2,4-Dinitrophenol|| | 2,4-Dinitrophenol|51-28-5|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0152 | ||
2,4-Dinitrotoluene|| | 2,4-Dinitrotoluene|121-14-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0542 | ||
2,4-/2,6-Dinitrotoluene mixture||Not Assessed under the IRIS program.|||||| | 2,4-/2,6-Dinitrotoluene mixture||Not Assessed under the IRIS program.|||||| | ||
Dinoseb||Not Assessed under the IRIS program.|||||| | Dinoseb||Not Assessed under the IRIS program.|||||| | ||
1,4-Dioxane|| | 1,4-Dioxane|123-91-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0326 | ||
Diphenamid||Not Assessed under the IRIS program.|||||| | Diphenamid||Not Assessed under the IRIS program.|||||| | ||
Diphenylamine||Not Assessed under the IRIS program.|||||| | Diphenylamine||Not Assessed under the IRIS program.|||||| | ||
1,2-Diphenylhydrazine|| | 1,2-Diphenylhydrazine|122-66-7|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0049 | ||
Diquat||Not Assessed under the IRIS program.|||||| | Diquat||Not Assessed under the IRIS program.|||||| | ||
Disulfoton||Not Assessed under the IRIS program.|||||| | Disulfoton||Not Assessed under the IRIS program.|||||| | ||
| Line 363: | Line 364: | ||
Endothall||Not Assessed under the IRIS program.|||||| | Endothall||Not Assessed under the IRIS program.|||||| | ||
Endrin||Not Assessed under the IRIS program.|||||| | Endrin||Not Assessed under the IRIS program.|||||| | ||
Epichlorohydrin|| | Epichlorohydrin|106-89-8|Changes in the nasal turbinates|mg /m<sup>3</sup>|1x10<sup>-3</sup>|NOAEL (HEC)|0.36|Medium|0050 | ||
1,2-Epoxybutane (EBU)|| | 1,2-Epoxybutane (EBU)|106-88-7|Degenerative lesions of the nasal cavity|mg /m<sup>3</sup>|2x10<sup>-2</sup>|LOAEL (HEC)|4.8|Medium|0630 | ||
Ethephon||Not Assessed under the IRIS program.|||||| | Ethephon||Not Assessed under the IRIS program.|||||| | ||
Ethion||Not Assessed under the IRIS program.|||||| | Ethion||Not Assessed under the IRIS program.|||||| | ||
2-Ethoxyethanol|| | 2-Ethoxyethanol|110-80-5|Decreased testis weight, seminiferous tubule degeneration and decreased hemoglobin|mg /m<sup>3</sup>|2x10<sup>-1</sup>|NOAEL (HEC)|68|Medium|0513 | ||
Ethyl acetate||Not Assessed under the IRIS program.|||||| | Ethyl acetate||Not Assessed under the IRIS program.|||||| | ||
Ethyl carbamate|| | Ethyl carbamate|51-79-6|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0629 | ||
Ethyl chloride|| | Ethyl chloride|75-00-3|Delayed fetal ossification|mg /m<sup>3</sup>|1x10<sup>1<7sup>|NOAEL (HEC)|4000|Medium|0523 | ||
S-Ethyl dipropylthiocarbamate (EPTC)||Not Assessed under the IRIS program.|||||| | S-Ethyl dipropylthiocarbamate (EPTC)||Not Assessed under the IRIS program.|||||| | ||
Ethyl ether||Not Assessed under the IRIS program.|||||| | Ethyl ether||Not Assessed under the IRIS program.|||||| | ||
Ethyl p-nitrophenyl phenylphosphorothioate (EPN)||Not Assessed under the IRIS program.|||||| | Ethyl p-nitrophenyl phenylphosphorothioate (EPN)||Not Assessed under the IRIS program.|||||| | ||
Ethylbenzene|| | Ethylbenzene|100-41-4|Developmental toxicity|mg /m<sup>3</sup>|1|NOAEL (HEC)|434|Low|0051 | ||
Ethylene diamine|| | Ethylene diamine|107-15-3|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0528 | ||
Ethylene glycol||Not Assessed under the IRIS program.|||||| | Ethylene glycol||Not Assessed under the IRIS program.|||||| | ||
Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol)|| | Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol)|111-76-2|Hemosiderin deposition in the liver|mg /m<sup>3</sup>|1.6|BMCL (HEC)|16|Medium/High|0500 | ||
Ethylene thiourea (ETU)||Not Assessed under the IRIS program.|||||| | Ethylene thiourea (ETU)||Not Assessed under the IRIS program.|||||| | ||
Ethyleneimine|| | Ethyleneimine|151-56-4|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0631 | ||
Ethylphthalyl ethylglycolate (EPEG)||Not Assessed under the IRIS program.|||||| | Ethylphthalyl ethylglycolate (EPEG)||Not Assessed under the IRIS program.|||||| | ||
Express||Not Assessed under the IRIS program.|||||| | Express||Not Assessed under the IRIS program.|||||| | ||
| Line 410: | Line 411: | ||
Hexabromobenzene||Not Assessed under the IRIS program.|||||| | Hexabromobenzene||Not Assessed under the IRIS program.|||||| | ||
Hexabromodiphenyl ether||Not Assessed under the IRIS program.|||||| | Hexabromodiphenyl ether||Not Assessed under the IRIS program.|||||| | ||
2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153)|| | 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153)|68631-49-2|Information reviewed but value not estimated. Refer to IRIS Summary.||||||1009 | ||
Hexachlorobenzene|| | Hexachlorobenzene|118-74-1|Information reviewed but value not estimated. Refer to IRIS Summary.||||||0374 | ||
Hexachlorobutadiene||Not Assessed under the IRIS program.|||||| | Hexachlorobutadiene||Not Assessed under the IRIS program.|||||| | ||
alpha-Hexachlorocyclohexane (alpha-HCH)||Not Assessed under the IRIS program.|||||| | alpha-Hexachlorocyclohexane (alpha-HCH)||Not Assessed under the IRIS program.|||||| | ||
| Line 419: | Line 420: | ||
gamma-Hexachlorocyclohexane (gamma-HCH)||Not Assessed under the IRIS program.|||||| | gamma-Hexachlorocyclohexane (gamma-HCH)||Not Assessed under the IRIS program.|||||| | ||
technical Hexachlorocyclohexane (t-HCH)||Not Assessed under the IRIS program.|||||| | technical Hexachlorocyclohexane (t-HCH)||Not Assessed under the IRIS program.|||||| | ||
Hexachlorocyclopentadiene (HCCPD)|| | Hexachlorocyclopentadiene (HCCPD)|77-47-4|Suppurative inflammation of the nose|mg /m<sup>3</sup>|2x10<sup>-4</sup>|NOAEL (HEC)|0.024|Medium|0059 | ||
Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD||Not Assessed under the IRIS program.|||||| | Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD||Not Assessed under the IRIS program.|||||| | ||
Hexachloroethane|| | Hexachloroethane|67-72-1|Neurotoxicity (tremors and ruffled pelt)|mg /m<sup>3</sup>|3x10<sup>-2</sup>|NOAEL (HEC)|83|Low|0167 | ||
Hexachlorophene||Not Assessed under the IRIS program.|||||| | Hexachlorophene||Not Assessed under the IRIS program.|||||| | ||
Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)||Not Assessed under the IRIS program.|||||| | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)||Not Assessed under the IRIS program.|||||| | ||
Revision as of 08:57, 26 June 2012
This page provides a description and a link to a "IRIS" database that provides information needed when modeling exposure levels or performing exposure assessment.
Short description
IRIS is a database of human health effects that may result from exposure to various substances found in the environment. The heart of the IRIS system is its collection of computer files covering individual chemicals. These chemical files contain descriptive and quantitative information in the following categories: a) Oral reference doses and inhalation reference concentrations (RfDs and RfCs, respectively) for chronic noncarcinogenic health effects, b) Hazard identification, oral slope factors, and oral and inhalation unit risks for carcinogenic effects. Database includes over 500 chemicals.
Long description
http://www.nlm.nih.gov/pubs/factsheets/irisfs.html
Link
Key words
human health effects, exposure, toxicology, carcinogenity, hazards
Data scrapping
IRIS database is accessible from this link: http://cfpub.epa.gov/ncea/iris/compare.cfm. The critical data can be obtained at once if all substances and all types of data are selected. A result is an html file with several tables from which the data can be scrapped and transformed into a better format. The January 4th, 2012, version was downloaded from IRIS and saved on this page (see the file below). Who could do this?
Reference system in IRIS database. The number (e.g. 0442) refers to the IRIS chemical identifier.
QuickView http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#reforal Oral RfDs http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#refinhal Inhalation RfCs http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#woe Weight-of-Evidence Characterizations http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#quaoral Oral Slope Factors/Drinking Water Unit Risks http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#quainhal Inhalation Unit Risks
IRIS Summary http://www.epa.gov/iris/subst/0442.htm#reforal http://www.epa.gov/iris/subst/0442.htm#refinhal http://www.epa.gov/iris/subst/0442.htm#woe http://www.epa.gov/iris/subst/0442.htm#quaoral http://www.epa.gov/iris/subst/0442.htm#quainhal
Toxicological Review (PDF) http://www.epa.gov/iris/toxreviews/0128tr.pdf (this does not exist for many compounds)
Oral RfDs
Oral RfDs were scrapped as an example (chemical starting with A) on Jan 4, 2012.
⇤--#: . Ei tätä kannata tehdä rivi kerrallaan, vaan ottaa koko viiden taulukon tiedosto (ks. Related files) muokata siitä tekstinkäsittelyohjelmalla viisi t2b-taulukkoa. Etsi-korvaa-toiminnolla voi tehdä suurimman osan muotoiluista. Kannattaa kysyä apua jos ei osaa, koska muuten työssä menee päiviä. --Jouni 10:42, 20 June 2012 (EEST) (type: truth; paradigms: science: attack)
⇤--#: . Huomaa, että IRIS identifier on tärkeä. Se löytyy nettilinkeistä (esim. Acenaphthenen QuickView on tämmöinen linkki: http://cfpub.epa.gov/ncea/iris/quickview.cfm?substance_nmbr=0442#reforal ja siitä näkee, että tämän aineen IRIS identifier on 0442. --Jouni 10:42, 20 June 2012 (EEST) (type: truth; paradigms: science: attack)
| Obs | Substance | CASRN | Critical Effact(s) | Unit | Oral RfD | Type of RfD | Point of Departure(s)* | Overall Confidence | IRIS identifier |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Acenaphthene | 83-32-9 | Hepatotoxicity | mg /kg-day | 6 x10-2 | NOAEL | 175 | Low | 0442 |
| 2 | Acenaphthylene | 208-96-8 | Not Assessed under the IRIS program | 0443 | |||||
| 3 | Acephate | 30560-19-1 | Inhibition of brain ChE | mg /kg-day | 4 x10-3 | LEL | 0.12 | High | 0354 |
| 4 | Acetaldehyde | 75-07-0 | Not Assessed under the IRIS program | 0290 | |||||
| 5 | Acetochlor | 34256-82-1 | Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males | mg /kg-day | 2 x10-2 | NOAEL | 2 mg/kg-day | High | 0521 |
| 6 | Acetone | 67-64-1 | Nephropathy | mg /kg-day | 0.9 | NOAEL | 900 | Medium | 0128 |
| 7 | Acetonitrile | 75-05-8 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0205 | |||||
| 8 | Acetophenone | 98-86-2 | General toxicity | mg /kg-day | 1 x10-1 | NOAEL | 423 | Low | 0321 |
| 9 | Acetyl chloride | 75-36-5 | Not Assessed under the IRIS program | 0518 | |||||
| 10 | Acifluorfen, sodium | 62476-59-9 | Mortality and kidney lesions | mg /kg-day | 1.3 x10-2 | NOEL | 1.25 | Medium | 0192 |
| 11 | Acrolein | 107-02-8 | Decreased survival | mg /kg-day | 5 x10-4 | NOAEL | 0.05 | Medium/High | 0364 |
| 12 | Acrylamide | 79-06-1 | Degenerative nerve changes | mg /kg-day | 0.002 | HED (BMDL) | 0.053 | Medium/High | 0286 |
| 13 | Acrylic acid | 79-10-7 | Reduced pup weight | mg /kg-day | 5 x10-1 | NOAEL | 53 | High | 0002 |
| 14 | Acrylonitrile | 107-13-1 | Not Assessed under the IRIS program | 0206 | |||||
| 15 | Adiponitrile | 111-69-3 | Not Assessed under the IRIS program | 0515 | |||||
| 16 | Alachlor | 15972-60-8 | Hemosiderosis, hemolytic anemia | mg /kg-day | 1 x10-2 | NOAEL | 1 | High | 0129 |
| 17 | Alar | 1596-84-5 | No adverse effects | mg /kg-day | 1.5 x10-1 | NOEL | 15 | Low | 0287 |
| 18 | Aldicarb | 116-06-3 | Sweating as clinical sign of AChe inhibition (other effect: Clinical signs and symptoms of acetylcholinesterase inhibition including sweating, pinpoint pupils, leg weakness, and other effects Nausea, diarrhea, and other signs and symptoms) | mg /kg-day | 1 x10-3 | NOAEL | 0.01 | Medium | 0003 |
| 19 | Aldicarb sulfone | 1646-88-4 | Brain ChE inhibition in females | mg /kg-day | 1 x10-3 | NOAEL | 0.11 | Medium | 0312 |
| 20 | Aldrin | 309-00-2 | Liver toxicity | mg /kg-day | 3 x10-5 | LOAEL | 0.025 | Medium | 0130 |
| 21 | Ally | 74223-64-6 | Decreased body weight | mg /kg-day | 2.5 x10-1 | NOEL | 25 | High | 0288 |
| 22 | Allyl alcohol | 107-18-6 | Impaired renal function and increased liver and kidney weights | mg /kg-day | 5 x10-3 | NOEL | 4.8 | Low | 0004 |
| 23 | Allyl chloride | 107-05-1 | Not Assessed under the IRIS program | 0387 | |||||
| 24 | Aluminum phosphide | 20859-73-8 | Body weight and clinical parameters | mg /kg-day | 4 x10-4 | NOAEL | 0.043 | Medium | 0005 |
| 25 | Amdro | 67485-29-4 | Increased organ weights | mg /kg-day | 3 x10-4 | NOEL | 0.33 | High | 0207 |
| 26 | Ametryn | 834-12-8 | Liver toxicity | mg /kg-day | 9 x10-3 | NOEL | 8.6 | Low | 0208 |
| 27 | 4-Aminopyridine | 504-24-5 | Not Assessed under the IRIS program | 0440 | |||||
| 28 | Amitraz | 33089-61-1 | Increased mean blood sugar concentration; slight hypothermia | mg /kg-day | 2.5 x10-3 | NOEL | 0.25 | Medium | 0334 |
| 29 | Ammonia | 7664-41-7 | Not Assessed under the IRIS program | 0422 | |||||
| 30 | Ammonium acetate | 631-61-8 | Not Assessed under the IRIS program | 0517 | |||||
| 31 | Ammonium methacrylate | 16325-47-6 | Not Assessed under the IRIS program | 0516 | |||||
| 32 | Ammonium sulfamate | 7773-06-0 | Decrease in body weight | mg /kg-day | 2 x10-1 | NOEL | 214.3 | Low | 0007 |
| 33 | Aniline | 62-53-3 | Not Assessed under the IRIS program | 0350 | |||||
| 34 | ortho-Anisidine | 90-04-0 | Not Assessed under the IRIS program | 0610 | |||||
| 35 | Anthracene | 120-12-7 | No observed effects | mg /kg-day | 3 x10-1 | NOEL | 1000 | Low | 0434 |
| 36 | Antimony | 7440-36-0 | Longevity, blood glucose, and cholesterol | mg /kg-day | 4 x10-4 | LOAEL | 0.35 | Low | 0006 |
| 37 | Antimony trioxide | 1309-64-4 | Not Assessed under the IRIS program | 0676 | |||||
| 38 | Apollo | 74115-24-5 | Liver effects; organ weight changes | mg /kg-day | 1.3 x10-2 | NOEL | 1.25 | High | 0008 |
| 39 | Aramite | 140-57-8 | Not Assessed under the IRIS program | 0473 | |||||
| 40 | Aroclor 1016 | 12674-11-2 | Reduced birth weights | mg /kg-day | 7 x10-5 | NOAEL | 0.007 | Medium | 0462 |
| 41 | Aroclor 1248 | 12672-29-6 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0649 | |||||
| 42 | Aroclor 1254 | 11097-69-1 | Ocular exudate, inflamed and prominent Meibomian glands, distorted growth of finger and toe nails; decreased antibody (IgG and IgM) response to sheep erythrocytes | mg /kg-day | 2 x10-5 | LOAEL | 0.005 | Medium | 0389 |
| 43 | Arsenic, inorganic | 7440-38-2 | Hyperpigmentation, keratosis and possible vascular complications | mg /kg-day | 3 x10-4 | NOAEL | 0.0008 | Medium | 0278 |
| 44 | Arsine | 7784-42-1 | Not Assessed under the IRIS program | 0672 | |||||
| 45 | Asbestos | 1332-21-4 | Not Assessed under the IRIS program | 0371 | |||||
| 46 | Assure | 76578-14-8 | Liver cell enlargement | mg /kg-day | 9 x10-3 | NOEL | 0.9 | High | 0335 |
| 47 | Asulam | 3337-71-1 | Lower ovarian weight, lower liver/body weight | mg /kg-day | 5 x10-2 | LEL | 50 | Medium | 0284 |
| 48 | Atrazine | 1912-24-9 | Decreased body weight gain (other effect: Cardiac toxicity and moderate-to-severe dilation of the right atrium) | mg /kg-day | 3.5 x10-2 | NOAEL | 3.5 | High | 0209 |
| 49 | Avermectin B1 | 65195-55-3 | Increased retinal folds in weanlings, decreased viability and lactation indices, decreased pup body weight, increase of dead pups at birth | mg /kg-day | 4 x10-4 | NOEL | 0.12 | High | 0381 |
| 50 | Azobenzene | 103-33-3 | Not Assessed under the IRIS program | 0351 | |||||
| 51 | Barium and Compounds | 7440-39-3 | Nephropathy | mg /kg-day | 0.2 | BMDL05 | 63 | Medium | 0010 |
| 52 | Barium cyanide | 542-62-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0009 | |||||
| 53 | Baygon | 114-26-1 | Mild cholinergic symptoms and RBD ChE inhibition | mg /kg-day | 4 x10-3 | LEL | 0.36 | Medium | 0210 |
| 54 | Bayleton | 43121-43-3 | Decreased body weight gain, erythrocyte count and hemoglobin level | mg /kg-day | 3 x10-2 | NOEL | 2.5 | High | 0131 |
| 55 | Baythroid | 68359-37-5 | Decreased body weights in males, inflammatory foci in kidneys of females | mg /kg-day | 2.5 x10-2 | NOEL | 2.5 | High | 0132 |
| 56 | Benefin | 1861-40-1 | Depressed erythrocyte counts | mg /kg-day | 3 x10-1 | NOAEL | 25 | Medium | 0133 |
| 57 | Benomyl | 17804-35-2 | Decreased pup weanling weights | mg /kg-day | 5 x10-2 | NOEL | 5 mg/kg-day | High | 0011 |
| 58 | Bentazon (Basagran) | 25057-89-0 | Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs (other effect: Dose-related increase in red areas (presumed blood) in feces; coagulation defect) | mg /kg-day | 3.0 x10-2 | NOAEL (ADJ) | 3.2 | Medium | 0134 |
| 59 | Benz[a]anthracene | 56-55-3 | Not Assessed under the IRIS program | 0454 | |||||
| 60 | Benzaldehyde | 100-52-7 | Forestomach lesions, kidney toxicity | mg /kg-day | 1 x10-1 | NOEL | 143 | Low | 0332 |
| 61 | Benzene | 71-43-2 | Decreased lymphocyte count | mg /kg-day | 4.0 x10-3 | BMDL | 1.2 | Medium | 0276 |
| 62 | Benzidine | 92-87-5 | Brain cell vacuolization; liver cell alterations in females | mg /kg-day | 3 x10-3 | LOAEL | 2.7 | Medium | 0135 |
Inhalation RfCs
| Obs | Substance | CASRN | Critical Effact(s) | Unit | Inhalation RfC | Type of RfC | Point of Departure(s)* | Overall Confidence | IRIS identifier |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Acenaphthene | 83-32-9 | Not Assessed under the IRIS program. | ||||||
| 2 | Acenaphthylene | 208-96-8 | Not Assessed under the IRIS program. | ||||||
| 3 | Acephate | 30560-19-1 | Not Assessed under the IRIS program. | ||||||
| 4 | Acetaldehyde | 75-07-0 | Degeneration of olfactory epithelium | mg /m3 | 9x10-3 | NOAEL (HEC) | 8.7 | Low | 0290 |
| 5 | Acetochlor | 34256-82-1 | Not Assessed under the IRIS program. | ||||||
| 6 | Acetone | 67-64-1 | Not Assessed under the IRIS program. | ||||||
| 7 | Acetonitrile | 75-05-8 | Not Assessed under the IRIS program. | ||||||
| 8 | Acetophenone | 98-86-2 | Mortality | mg /m3 | 6x10-2 | NOAEL (HEC) | 60 | Medium | 0205 |
| 9 | Acetyl chloride | Not Assessed under the IRIS program. | |||||||
| 10 | Acifluorfen, sodium | Not Assessed under the IRIS program. | |||||||
| 11 | Acrolein | Nasal lesions | mg /m3 | 2x10-5 | LOAEL (HEC) | 0.02 | Medium | 0364 | |
| 12 | Acrylamide | Degenerative nerve changes | mg /m3 | 0.006 | HEC (BMDL) | 0.18 | Medium | 0286 | |
| 13 | Acrylic acid | Degeneration of the nasal olfactory epithelium | mg /m3 | 1x10-3 | LOAEL (HEC) | 0.33 | Medium | 0002 | |
| 14 | Acrylonitrile | Degeneration and inflammation of nasal respiratory epithelium; hyperplasia of mucous secreting cells | mg /m3 | 2x10-3 | LOAEL (HEC) | 1.9 | Medium | 0206 | |
| 15 | Adiponitrile | Not Assessed under the IRIS program. | |||||||
| 16 | Alachlor | Not Assessed under the IRIS program. | |||||||
| 17 | Alar | Not Assessed under the IRIS program. | |||||||
| 18 | Aldicarb | Not Assessed under the IRIS program. | |||||||
| 19 | Aldicarb sulfone | Not Assessed under the IRIS program. | |||||||
| 20 | Aldrin | Not Assessed under the IRIS program. | |||||||
| 21 | Ally | Not Assessed under the IRIS program. | |||||||
| 22 | Allyl alcohol | Not Assessed under the IRIS program. | |||||||
| 23 | Allyl chloride | Functional and histological peripheral neurotoxicity | mg /m3 | 1x10-3 | NOAEL (HEC) | 3.6 | Low | 0387 | |
| 24 | Aluminum phosphide | Not Assessed under the IRIS program. | |||||||
| 25 | Amdro | Not Assessed under the IRIS program. | |||||||
| 26 | Ametryn | Not Assessed under the IRIS program. | |||||||
| 27 | 4-Aminopyridine | Not Assessed under the IRIS program. | |||||||
| 28 | Amitraz | Not Assessed under the IRIS program. | |||||||
| 29 | Ammonia | Not Assessed under the IRIS program. | |||||||
| 30 | Ammonium acetate | Not Assessed under the IRIS program. | |||||||
| 31 | Ammonium methacrylate | Not Assessed under the IRIS program. | |||||||
| 32 | Ammonium sulfamate | Not Assessed under the IRIS program. | |||||||
| 33 | Aniline | 62-53-3 | Lack of toxicity (other effect: Mild spleen toxicity ) | mg /m3 | 1x10-3 | NOAEL (HEC) | 3.4 | Low | 0350 |
| 34 | ortho-Anisidine | 90-04-0 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0610 | |||||
| 35 | Anthracene | Not Assessed under the IRIS program. | |||||||
| 36 | Antimony | Not Assessed under the IRIS program. | |||||||
| 37 | Antimony trioxide | 1309-64-4 | Pulmonary toxicity, chronic interstitial inflammation | mg /m3 | 2x10-4 | BMC10 (HEC) | 0.074 | Medium | 0676 |
| 38 | Apollo | Not Assessed under the IRIS program. | |||||||
| 39 | Aramite | Not Assessed under the IRIS program. | |||||||
| 40 | Aroclor 1016 | Not Assessed under the IRIS program. | |||||||
| 41 | Aroclor 1248 | Not Assessed under the IRIS program. | |||||||
| 42 | Aroclor 1254 | Not Assessed under the IRIS program. | |||||||
| 43 | Arsenic, inorganic | Not Assessed under the IRIS program. | |||||||
| 44 | Arsine | 7784-42-1 | Increased hemolysis, abnormal RBC morphology, and increased spleen weight (other effect: Increased hemolysis, increased spleen weight, and impaired compensatory erythropoiesis) | mg /m3 | 5x10-5 | NOAEL (HEC) | 0.014 | Medium | 0672 |
| 45 | Asbestos | Not Assessed under the IRIS program. | |||||||
| 46 | Assure | Not Assessed under the IRIS program. | |||||||
| 47 | Asulam | Not Assessed under the IRIS program. | |||||||
| 48 | Atrazine | Not Assessed under the IRIS program. | |||||||
| 49 | Avermectin B1 | Not Assessed under the IRIS program. | |||||||
| 50 | Azobenzene | Not Assessed under the IRIS program. | |||||||
| 51 | Barium and Compounds | Not Assessed under the IRIS program. | |||||||
| 52 | Barium cyanide | Not Assessed under the IRIS program. | |||||||
| 53 | Baygon | Not Assessed under the IRIS program. | |||||||
| 54 | Bayleton | Not Assessed under the IRIS program. | |||||||
| 55 | Baythroid | Not Assessed under the IRIS program. | |||||||
| 56 | Benefin | Not Assessed under the IRIS program. | |||||||
| 57 | Benomyl | Not Assessed under the IRIS program. | |||||||
| 58 | Bentazon (Basagran) | Not Assessed under the IRIS program. | |||||||
| 59 | Benz[a]anthracene | Not Assessed under the IRIS program. | |||||||
| 60 | Benzaldehyde | Not Assessed under the IRIS program. | |||||||
| 61 | Benzene | 71-43-2 | Decreased lymphocyte count | mg /m3 | 3x10-2 | BMCL | 8.2 | Medium | 0276 |
| 62 | Benzidine | 92-87-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0135 | |||||
| 63 | Benzo[a]pyrene (BaP) | Not Assessed under the IRIS program. | |||||||
| 64 | Benzo[b]fluoranthene | Not Assessed under the IRIS program. | |||||||
| 65 | Benzo[g,h,i]perylene | Not Assessed under the IRIS program. | |||||||
| 66 | Benzo[k]fluoranthene | Not Assessed under the IRIS program. | |||||||
| 67 | Benzoic acid | Not Assessed under the IRIS program. | |||||||
| 68 | Benzotrichloride | Not Assessed under the IRIS program. | |||||||
| 69 | Benzyl chloride | 100-44-7 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0393 | |||||
| 70 | Beryllium and compounds | 7440-41-7 | Beryllium sensitization and progression to CBD | mg /m3 | 2x10-5 | LOAEL (HEC) | 0.0002 | Medium | 0012 |
| 71 | Bidrin | Not Assessed under the IRIS program. | |||||||
| 72 | Biphenthrin | Not Assessed under the IRIS program. | |||||||
| 73 | 1,1-Biphenyl | 92-52-4 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0013 | |||||
| 74 | Bis(2-chloro-1-methylethyl) ether | Not Assessed under the IRIS program. | |||||||
| 75 | Bis(2-chloroethoxy)methane | Not Assessed under the IRIS program. | |||||||
| 76 | Bis(chloroethyl)ether (BCEE) | 111-44-4 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0137 | |||||
| 77 | Bis(chloromethyl)ether (BCME) | 542-88-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0375 | |||||
| 78 | Bisphenol A. | 80-05-7 | Not Assessed under the IRIS program. | ||||||
| 79 | Boron and Compounds | Information reviewed but value not estimated. Refer to IRIS Summary. | 0410 | ||||||
| 80 | Bromate | 15541-45-4 | Information reviewed but value not estimated. Refer to IRIS Summary. | 1002 | |||||
| 81 | Brominated dibenzofurans | NA | Not Assessed under the IRIS program. | ||||||
| 82 | Bromobenzene | 108-86-1 | Hepatocellular cytomegaly in female B6C3F1 mice | mg /m3 | 6x10-2 | BMCL10 (HEC) | 63 | Low/Medium | 1020 |
| 83 | Bromochloromethane | Not Assessed under the IRIS program. | |||||||
| 84 | Bromodichloromethane | Not Assessed under the IRIS program. | |||||||
| 85 | p-Bromodiphenyl ether | Not Assessed under the IRIS program. | |||||||
| 86 | Bromoform | 75-25-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0214 | |||||
| 87 | Bromomethane | 74-83-9 | Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity | mg /m3 | 5x10-3 | LOAEL (HEC) | 0.48 | High | 0015 |
| 88 | Bromotrichloromethane | Not Assessed under the IRIS program. | |||||||
| 89 | Bromoxynil | Not Assessed under the IRIS program. | |||||||
| 90 | Bromoxynil octanoate | Not Assessed under the IRIS program. | |||||||
| 91 | 1,3-Butadiene | 106-99-0 | Ovarian atrophy | mg /m3 | 2x10-3 | BMCL10 (HEC) | 1.98 | Medium | 0139 |
| 92 | n-Butanol | Not Assessed under the IRIS program. | |||||||
| 93 | Butyl benzyl phthalate | Not Assessed under the IRIS program. | |||||||
| 94 | Butylate | Not Assessed under the IRIS program. | |||||||
| 95 | t-Butylchloride | Not Assessed under the IRIS program. | |||||||
| 96 | Butylphthalyl butylglycolate (BPBG) | Not Assessed under the IRIS program. | |||||||
| 97 | Cacodylic acid | Not Assessed under the IRIS program. | |||||||
| 98 | Cadmium | Not Assessed under the IRIS program. | |||||||
| 99 | Calcium cyanide | Not Assessed under the IRIS program. | |||||||
| 100 | Caprolactam | 105-60-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0357 | |||||
| 101 | Captafol | Not Assessed under the IRIS program. | |||||||
| 102 | Captan | Not Assessed under the IRIS program. | |||||||
| 103 | Carbaryl | 63-25-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0019 | |||||
| 104 | Carbofuran | Not Assessed under the IRIS program. | |||||||
| 105 | Carbon disulfide | 75-15-0 | Peripheral nervous system dysfunction | mg /m3 | 7x10-1 | BMC10 (HEC) | 19.7 | Medium | 0217 |
| 106 | Carbon tetrachloride | 56-23-5 | Not Assessed under the IRIS program. | Fatty changes in the liver | mg /m3 | 0.1 | BMCL10 (HEC) | 14.3 | 0020 |
| 107 | Carbonyl sulfide | 463-58-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0617 | |||||
| 108 | Carbosulfan | Not Assessed under the IRIS program. | |||||||
| 109 | Carboxin | Not Assessed under the IRIS program. | |||||||
| 110 | Cerium Oxide and Cerium Compounds | 1306-38-3 | Increased incidence of alveolar epithelial hyperplasia in the lungs of male and female rats | mg /m3 | 9x10-4 | BMCL (HEC) | 0.86 | Low | 1018 |
| 111 | Chloral hydrate | Not Assessed under the IRIS program. | |||||||
| 112 | Chloramben | Not Assessed under the IRIS program. | |||||||
| 113 | Chlordane (Technical) | 12789-03-6 | Hepatic effects | mg /m3 | 7x10-4 | NOAEL (HEC) | 0.65 | Low | 0142 |
| 114 | Chlordecone (Kepone) | 143-50-0 | Information reviewed but value not estimated. Refer to IRIS Summary. | 1017 | |||||
| 115 | Chlorimuron-ethyl | Not Assessed under the IRIS program. | |||||||
| 116 | Chlorine | Not Assessed under the IRIS program. | |||||||
| 117 | Chlorine cyanide | Not Assessed under the IRIS program. | |||||||
| 118 | Chlorine dioxide | 10049-04-4 | Vascular congestion and peribronchial edema (other effect: Hemorrhagic alveoli and congested capillaries in the lungs) | mg /m3 | 2x10-4 | LOAEL (HEC) | 0.64 | Low | 0496 |
| 119 | Chlorite (sodium salt) | 7758-19-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0648 | |||||
| 120 | 1-Chloro-1,1-difluoroethane | 75-68-3 | No adverse effects | mg /m3 | 5x101 | NOAEL (HEC) | 14710 | Medium | 0661 |
| 121 | 2-Chloroacetophenone | 532-27-4 | Squamous hyperplasia of the nasal respiratory epithelium | mg /m3 | 3x10-5 | LOAEL (HEC) | 0.03 | Low | 0537 |
| 122 | p-Chloroaniline | Not Assessed under the IRIS program. | |||||||
| 123 | Chlorobenzene | Not Assessed under the IRIS program. | |||||||
| 124 | Chlorobenzilate | Not Assessed under the IRIS program. | |||||||
| 125 | 1-Chlorobutane | Not Assessed under the IRIS program. | |||||||
| 126 | 2-Chlorobutane | Not Assessed under the IRIS program. | |||||||
| 127 | Chlorocyclopentadiene | Not Assessed under the IRIS program. | |||||||
| 128 | Chlorodifluoromethane | 75-45-6 | Increased kidney, adrenal and pituitary weights (other effect: Reduced maternal weight gain) | mg /m3 | 5x101 | NOAEL (HEC) | 5260 | Medium | 0657 |
| 129 | Chloroform | Not Assessed under the IRIS program. | |||||||
| 130 | Chloromethyl methyl ether (CMME) | Not Assessed under the IRIS program. | |||||||
| 131 | beta-Chloronaphthalene | Not Assessed under the IRIS program. | |||||||
| 132 | 2-Chlorophenol | Not Assessed under the IRIS program. | |||||||
| 133 | p-Chlorophenyl methyl sulfide | Not Assessed under the IRIS program. | |||||||
| 134 | p-Chlorophenyl methyl sulfone | Not Assessed under the IRIS program. | |||||||
| 135 | p-Chlorophenyl methyl sulfoxide | Not Assessed under the IRIS program. | |||||||
| 136 | Chloroprene | 126-99-8 | Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively | mg /m3 | 2x10-2 | BMDL (HEC) | 2 | Medium/High | 1021 |
| 137 | Chlorothalonil | Not Assessed under the IRIS program. | |||||||
| 138 | o-Chlorotoluene | Not Assessed under the IRIS program. | |||||||
| 139 | Chlorpropham | Not Assessed under the IRIS program. | |||||||
| 140 | Chlorpyrifos | Not Assessed under the IRIS program. | |||||||
| 141 | Chlorsulfuron | Not Assessed under the IRIS program. | |||||||
| 142 | Chromium(III), insoluble salts | 16065-83-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0028 | |||||
| 143 | Chromium(VI) (Chromic acid mists and dissolved Cr(VI) aerosols) | 18540-29-9 | Nasal septum atrophy | mg /m3 | 8x10-6 | LOAEL (ADJ) | 0.000714 | Low | 0144 |
| 144 | Chromium(VI) (Cr(VI) particulates) | 18540-29-9 | Lactate dehydrogenase in bronchioalveolar lavage fluid | 1x10-4 | BMC10 (ADJ) | 0.034 | Medium | 0144 | |
| 145 | Chrysene | Not Assessed under the IRIS program. | |||||||
| 146 | Coke oven emissions | Not Assessed under the IRIS program. | |||||||
| 147 | Copper | Not Assessed under the IRIS program. | |||||||
| 148 | Copper cyanide | Not Assessed under the IRIS program. | |||||||
| 149 | Creosote | Not Assessed under the IRIS program. | |||||||
| 150 | Crotonaldehyde | Not Assessed under the IRIS program. | |||||||
| 151 | Cumene | 98-82-8 | Increased kidney weights in female rats and adrenal weights in male and female rats | mg /m3 | 4x10-1 | NOAEL (HEC) | 435 | Medium | 0306 |
| 152 | Cyanazine | Not Assessed under the IRIS program. | |||||||
| 153 | Cyanide, free | Not Assessed under the IRIS program. | |||||||
| 154 | Cyanogen | Not Assessed under the IRIS program. | |||||||
| 155 | Cyanogen bromide | Not Assessed under the IRIS program. | |||||||
| 156 | Cyclohexane | 110-82-7 | Reduced pup weights in the F1 and F2 generations | mg /m3 | 6 | BMCL1sd (HEC) | 1822 | Low/Medium | 1005 |
| 157 | Cyclohexanone | Not Assessed under the IRIS program. | |||||||
| 158 | Cyclohexylamine | Not Assessed under the IRIS program. | |||||||
| 159 | Cyhalothrin/Karate | Not Assessed under the IRIS program. | |||||||
| 160 | Cypermethrin | Not Assessed under the IRIS program. | |||||||
| 161 | Cyromazine | Not Assessed under the IRIS program. | |||||||
| 162 | Dacthal | Not Assessed under the IRIS program. | |||||||
| 163 | Dalapon, sodium salt | Not Assessed under the IRIS program. | |||||||
| 164 | Danitol | Not Assessed under the IRIS program. | |||||||
| 165 | 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) | 1163-19-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0035 | |||||
| 166 | Demeton | Not Assessed under the IRIS program. | |||||||
| 167 | Di (2-ethylhexyl)phthalate (DEHP) | Not Assessed under the IRIS program. | |||||||
| 168 | Di(2-ethylhexyl)adipate | Not Assessed under the IRIS program. | |||||||
| 169 | 2,4-Diaminotoluene | 95-80-7 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0536 | |||||
| 170 | Diazomethane | 334-88-3 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0616 | |||||
| 171 | Dibenz[a,h]anthracene | Not Assessed under the IRIS program. | |||||||
| 172 | Dibenzofuran | Not Assessed under the IRIS program. | |||||||
| 173 | 1,2-Dibromo-3-chloropropane (DBCP) | 96-12-8 | Testicular effects | mg /m3 | 2x10-4 | NOAEL (HEC) | 0.17 | Medium | 0414 |
| 174 | 1,4-Dibromobenzene | Not Assessed under the IRIS program. | |||||||
| 175 | Dibromochloromethane | Not Assessed under the IRIS program. | |||||||
| 176 | Dibromodichloromethane | Not Assessed under the IRIS program. | |||||||
| 177 | p,p'-Dibromodiphenyl ether | Not Assessed under the IRIS program. | |||||||
| 178 | 1,2-Dibromoethane | 106-93-4 | Nasal inflammation | mg /m3 | 9x10-3 | BMCL10 (HEC) | 2.8 | Medium | 0361 |
| 179 | Dibutyl phthalate | 84-74-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0038 | |||||
| 180 | Dicamba | Not Assessed under the IRIS program. | |||||||
| 181 | Dichloroacetic acid | 79-43-6 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0654 | |||||
| 182 | 1,3-Dichlorobenzene | Not Assessed under the IRIS program. | |||||||
| 183 | 1,4-Dichlorobenzene | 106-46-7 | Increased liver weights in P1 males | mg /m3 | 8x10-1 | NOAEL (HEC) | 75 | Medium | 0552 |
| 184 | 1,2-Dichlorobenzene | Not Assessed under the IRIS program. | |||||||
| 185 | 3,3'-Dichlorobenzidine | 91-94-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0504 | |||||
| 186 | Dichlorodifluoromethane | Not Assessed under the IRIS program. | |||||||
| 187 | p,p'-Dichlorodiphenyl dichloroethane (DDD) | Not Assessed under the IRIS program. | |||||||
| 188 | p,p'-Dichlorodiphenyldichloroethylene (DDE) | Not Assessed under the IRIS program. | |||||||
| 189 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | Not Assessed under the IRIS program. | |||||||
| 190 | 1,2-Dichloroethane | Not Assessed under the IRIS program. | |||||||
| 191 | 1,1-Dichloroethane | Not Assessed under the IRIS program. | |||||||
| 192 | trans-1,2-Dichloroethylene | 156-60-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0314 | |||||
| 193 | cis-1,2-Dichloroethylene | 156-59-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0418 | |||||
| 194 | 1,1-Dichloroethylene (1,1-DCE) | 75-35-4 | Liver toxicity (fatty change) | mg /m3 | 2x10-1 | BMCL10 (HEC) | 6.9 | Medium | 0039 |
| 195 | Dichloromethane | 75-09-2 | Hepatic effects (hepatic vacuolation) | mg /m3 | 6x10-1 | BMDL10 (HEC) | 17.2 | Medium/High | 0070 |
| 196 | 2,4-Dichlorophenol | Not Assessed under the IRIS program. | |||||||
| 197 | 4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB) | Not Assessed under the IRIS program. | |||||||
| 198 | 2,4-Dichlorophenoxyacetic acid (2,4-D) | Not Assessed under the IRIS program. | |||||||
| 199 | 1,2-Dichloropropane | 78-87-5 | Hyperplasia of the nasal mucosa | mg /m3 | 4x10-3 | LOAEL (HEC) | 1.3 | Medium | 0601 |
| 200 | 2,3-Dichloropropanol | Not Assessed under the IRIS program. | |||||||
| 201 | 1,3-Dichloropropene | 542-75-6 | Hypertrophy/ hyperplasia of the nasal respiratory epithelium | mg /m3 | 2x10-2 | BMCL10 (HEC) | 0.72 | High | 0224 |
| 202 | Dichlorvos | 62-73-7 | Decreased brain cholinesterase activity | mg /m3 | 5x10-4 | NOAEL (HEC) | 0.05 | Medium | 0151 |
| 203 | Dicofol | Not Assessed under the IRIS program. | |||||||
| 204 | Dieldrin | Not Assessed under the IRIS program. | |||||||
| 205 | Diesel engine exhaust | NA | Pulmonary inflammation and histopathology | mg /m3 | 5x10-3 | NOAEL (HEC) | 0.144 | Medium | 0642 |
| 206 | Diethyl phthalate | Not Assessed under the IRIS program. | |||||||
| 207 | Diethyl sulfate | 64-67-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0615 | |||||
| 208 | Diethyl-p-nitrophenylphosphate | Not Assessed under the IRIS program. | |||||||
| 209 | Diethylene glycol dinitrate (DEGDN) | Not Assessed under the IRIS program. | |||||||
| 210 | Difenzoquat | Not Assessed under the IRIS program. | |||||||
| 211 | Diflubenzuron | Not Assessed under the IRIS program. | |||||||
| 212 | 1,1-Difluoroethane | 75-37-6 | No adverse effects observed | mg /m3 | 4x101 | NOAEL (HEC) | 12051 | Medium | 0665 |
| 213 | Diisopropyl methylphosphonate (DIMP) | Not Assessed under the IRIS program. | |||||||
| 214 | Dimethipin | Not Assessed under the IRIS program. | |||||||
| 215 | Dimethoate | Not Assessed under the IRIS program. | |||||||
| 216 | Dimethyl phthalate | 131-11-3 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0353 | |||||
| 217 | Dimethyl sulfate | 77-78-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0365 | |||||
| 218 | Dimethyl terephthalate (DMT) | Not Assessed under the IRIS program. | |||||||
| 219 | Dimethylamine | 124-40-3 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0228 | |||||
| 220 | N-N-Dimethylaniline | Not Assessed under the IRIS program. | |||||||
| 221 | 3,3-Dimethylbenzidine | 119-93-7 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0538 | |||||
| 222 | N,N-Dimethylformamide | 68-12-2 | Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities | mg /m3 | 3x10-2 | LOAEL (HEC) | 7.9 | Medium | 0511 |
| 223 | 3,4-Dimethylphenol | Not Assessed under the IRIS program. | |||||||
| 224 | 2,6-Dimethylphenol | Not Assessed under the IRIS program. | |||||||
| 225 | 2,4-Dimethylphenol | Not Assessed under the IRIS program. | |||||||
| 226 | 4,6-Dinitro-o-cyclohexyl phenol | Not Assessed under the IRIS program. | |||||||
| 227 | m-Dinitrobenzene | Not Assessed under the IRIS program. | |||||||
| 228 | o-Dinitrobenzene | Not Assessed under the IRIS program. | |||||||
| 229 | 2,4-Dinitrophenol | 51-28-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0152 | |||||
| 230 | 2,4-Dinitrotoluene | 121-14-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0542 | |||||
| 231 | 2,4-/2,6-Dinitrotoluene mixture | Not Assessed under the IRIS program. | |||||||
| 232 | Dinoseb | Not Assessed under the IRIS program. | |||||||
| 233 | 1,4-Dioxane | 123-91-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0326 | |||||
| 234 | Diphenamid | Not Assessed under the IRIS program. | |||||||
| 235 | Diphenylamine | Not Assessed under the IRIS program. | |||||||
| 236 | 1,2-Diphenylhydrazine | 122-66-7 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0049 | |||||
| 237 | Diquat | Not Assessed under the IRIS program. | |||||||
| 238 | Disulfoton | Not Assessed under the IRIS program. | |||||||
| 239 | 1,4-Dithiane | Not Assessed under the IRIS program. | |||||||
| 240 | Diuron | Not Assessed under the IRIS program. | |||||||
| 241 | Dodine | Not Assessed under the IRIS program. | |||||||
| 242 | Endosulfan | Not Assessed under the IRIS program. | |||||||
| 243 | Endothall | Not Assessed under the IRIS program. | |||||||
| 244 | Endrin | Not Assessed under the IRIS program. | |||||||
| 245 | Epichlorohydrin | 106-89-8 | Changes in the nasal turbinates | mg /m3 | 1x10-3 | NOAEL (HEC) | 0.36 | Medium | 0050 |
| 246 | 1,2-Epoxybutane (EBU) | 106-88-7 | Degenerative lesions of the nasal cavity | mg /m3 | 2x10-2 | LOAEL (HEC) | 4.8 | Medium | 0630 |
| 247 | Ethephon | Not Assessed under the IRIS program. | |||||||
| 248 | Ethion | Not Assessed under the IRIS program. | |||||||
| 249 | 2-Ethoxyethanol | 110-80-5 | Decreased testis weight, seminiferous tubule degeneration and decreased hemoglobin | mg /m3 | 2x10-1 | NOAEL (HEC) | 68 | Medium | 0513 |
| 250 | Ethyl acetate | Not Assessed under the IRIS program. | |||||||
| 251 | Ethyl carbamate | 51-79-6 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0629 | |||||
| 252 | Ethyl chloride | 75-00-3 | Delayed fetal ossification | mg /m3 | 1x101<7sup> | NOAEL (HEC) | 4000 | Medium | 0523 |
| 253 | S-Ethyl dipropylthiocarbamate (EPTC) | Not Assessed under the IRIS program. | |||||||
| 254 | Ethyl ether | Not Assessed under the IRIS program. | |||||||
| 255 | Ethyl p-nitrophenyl phenylphosphorothioate (EPN) | Not Assessed under the IRIS program. | |||||||
| 256 | Ethylbenzene | 100-41-4 | Developmental toxicity | mg /m3 | 1 | NOAEL (HEC) | 434 | Low | 0051 |
| 257 | Ethylene diamine | 107-15-3 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0528 | |||||
| 258 | Ethylene glycol | Not Assessed under the IRIS program. | |||||||
| 259 | Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | Hemosiderin deposition in the liver | mg /m3 | 1.6 | BMCL (HEC) | 16 | Medium/High | 0500 |
| 260 | Ethylene thiourea (ETU) | Not Assessed under the IRIS program. | |||||||
| 261 | Ethyleneimine | 151-56-4 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0631 | |||||
| 262 | Ethylphthalyl ethylglycolate (EPEG) | Not Assessed under the IRIS program. | |||||||
| 263 | Express | Not Assessed under the IRIS program. | |||||||
| 264 | Fenamiphos | Not Assessed under the IRIS program. | |||||||
| 265 | Fluometuron | Not Assessed under the IRIS program. | |||||||
| 266 | Fluoranthene | Not Assessed under the IRIS program. | |||||||
| 267 | Fluorene | Not Assessed under the IRIS program. | |||||||
| 268 | Fluorine (soluble fluoride) | Not Assessed under the IRIS program. | |||||||
| 269 | Fluridone | Not Assessed under the IRIS program. | |||||||
| 270 | Flurprimidol | Not Assessed under the IRIS program. | |||||||
| 271 | Flutolanil | Not Assessed under the IRIS program. | |||||||
| 272 | Fluvalinate | Not Assessed under the IRIS program. | |||||||
| 273 | Folpet | Not Assessed under the IRIS program. | |||||||
| 274 | Fomesafen | Not Assessed under the IRIS program. | |||||||
| 275 | Fonofos | Not Assessed under the IRIS program. | |||||||
| 276 | Formaldehyde | Not Assessed under the IRIS program. | |||||||
| 277 | Formic acid | Not Assessed under the IRIS program. | |||||||
| 278 | Fosetyl-al | Not Assessed under the IRIS program. | |||||||
| 279 | Furan | Not Assessed under the IRIS program. | |||||||
| 280 | Furfural | Not Assessed under the IRIS program. | |||||||
| 281 | Furmecyclox | Not Assessed under the IRIS program. | |||||||
| 282 | Glufosinate-ammonium | Not Assessed under the IRIS program. | |||||||
| 283 | Glycidaldehyde | Not Assessed under the IRIS program. | |||||||
| 284 | Glyphosate | Not Assessed under the IRIS program. | |||||||
| 285 | Haloxyfop-methyl | Not Assessed under the IRIS program. | |||||||
| 286 | Harmony | Not Assessed under the IRIS program. | |||||||
| 287 | Heptachlor | Not Assessed under the IRIS program. | |||||||
| 288 | Heptachlor epoxide | Not Assessed under the IRIS program. | |||||||
| 289 | n-Heptane | Not Assessed under the IRIS program. | |||||||
| 290 | Hexabromobenzene | Not Assessed under the IRIS program. | |||||||
| 291 | Hexabromodiphenyl ether | Not Assessed under the IRIS program. | |||||||
| 292 | 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) | 68631-49-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 1009 | |||||
| 293 | Hexachlorobenzene | 118-74-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0374 | |||||
| 294 | Hexachlorobutadiene | Not Assessed under the IRIS program. | |||||||
| 295 | alpha-Hexachlorocyclohexane (alpha-HCH) | Not Assessed under the IRIS program. | |||||||
| 296 | beta-Hexachlorocyclohexane (beta-HCH) | Not Assessed under the IRIS program. | |||||||
| 297 | delta-Hexachlorocyclohexane (delta-HCH) | Not Assessed under the IRIS program. | |||||||
| 298 | epsilon-Hexachlorocyclohexane (epsilon-HC) | Not Assessed under the IRIS program. | |||||||
| 299 | gamma-Hexachlorocyclohexane (gamma-HCH) | Not Assessed under the IRIS program. | |||||||
| 300 | technical Hexachlorocyclohexane (t-HCH) | Not Assessed under the IRIS program. | |||||||
| 301 | Hexachlorocyclopentadiene (HCCPD) | 77-47-4 | Suppurative inflammation of the nose | mg /m3 | 2x10-4 | NOAEL (HEC) | 0.024 | Medium | 0059 |
| 302 | Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD | Not Assessed under the IRIS program. | |||||||
| 303 | Hexachloroethane | 67-72-1 | Neurotoxicity (tremors and ruffled pelt) | mg /m3 | 3x10-2 | NOAEL (HEC) | 83 | Low | 0167 |
| 304 | Hexachlorophene | Not Assessed under the IRIS program. | |||||||
| 305 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | Not Assessed under the IRIS program. | |||||||
| 306 | 1,6-Hexamethylene diisocyanate | Not Assessed under the IRIS program. | |||||||
| 307 | n-Hexane | Not Assessed under the IRIS program. | |||||||
| 308 | 2-Hexanone | Not Assessed under the IRIS program. | |||||||
| 309 | Hexazinone | Not Assessed under the IRIS program. | |||||||
| 310 | Hydrazine/Hydrazine sulfate | Not Assessed under the IRIS program. | |||||||
| 311 | Hydrogen Cyanide and Cyanide Salts | Not Assessed under the IRIS program. | |||||||
| 312 | Hydrogen chloride | Not Assessed under the IRIS program. | |||||||
| 313 | Hydrogen sulfide | Not Assessed under the IRIS program. | |||||||
| 314 | Hydroquinone | Not Assessed under the IRIS program. | |||||||
| 315 | Imazalil | Not Assessed under the IRIS program. | |||||||
| 316 | Imazaquin | Not Assessed under the IRIS program. | |||||||
| 317 | Indeno[1,2,3-cd]pyrene | Not Assessed under the IRIS program. | |||||||
| 318 | Iprodione | Not Assessed under the IRIS program. | |||||||
| 319 | Isobutyl alcohol | Not Assessed under the IRIS program. | |||||||
| 320 | Isophorone | Not Assessed under the IRIS program. | |||||||
| 321 | Isopropalin | Not Assessed under the IRIS program. | |||||||
| 322 | Isopropyl methyl phosphonic acid (IMPA) | Not Assessed under the IRIS program. | |||||||
| 323 | Isoxaben | Not Assessed under the IRIS program. | |||||||
| 324 | Lactofen | Not Assessed under the IRIS program. | |||||||
| 325 | Lead and compounds (inorganic) | Not Assessed under the IRIS program. | |||||||
| 326 | d-Limonene | Not Assessed under the IRIS program. | |||||||
| 327 | Linuron | Not Assessed under the IRIS program. | |||||||
| 328 | Londax | Not Assessed under the IRIS program. | |||||||
| 329 | Malathion | Not Assessed under the IRIS program. | |||||||
| 330 | Maleic anhydride | Not Assessed under the IRIS program. | |||||||
| 331 | Maleic hydrazide | Not Assessed under the IRIS program. | |||||||
| 332 | Maneb | Not Assessed under the IRIS program. | |||||||
| 333 | Manganese | Not Assessed under the IRIS program. | |||||||
| 334 | Mepiquat chloride | Not Assessed under the IRIS program. | |||||||
| 335 | Mercuric chloride (HgCl2) | Not Assessed under the IRIS program. | |||||||
| 336 | Mercury, elemental | Not Assessed under the IRIS program. | |||||||
| 337 | Merphos | Not Assessed under the IRIS program. | |||||||
| 338 | Merphos oxide | Not Assessed under the IRIS program. | |||||||
| 339 | Metalaxyl | Not Assessed under the IRIS program. | |||||||
| 340 | Methacrylonitrile | Not Assessed under the IRIS program. | |||||||
| 341 | Methamidophos | Not Assessed under the IRIS program. | |||||||
| 342 | Methanol | Not Assessed under the IRIS program. | |||||||
| 343 | Methidathion | Not Assessed under the IRIS program. | |||||||
| 344 | Methomyl | Not Assessed under the IRIS program. | |||||||
| 345 | Methoxychlor | Not Assessed under the IRIS program. | |||||||
| 346 | 2-Methoxyethanol | Not Assessed under the IRIS program. | |||||||
| 347 | Methyl acrylate | Not Assessed under the IRIS program. | |||||||
| 348 | Methyl chloride | Not Assessed under the IRIS program. | |||||||
| 349 | Methyl chlorocarbonate | Not Assessed under the IRIS program. | |||||||
| 350 | Methyl ethyl ketone (MEK) | Not Assessed under the IRIS program. | |||||||
| 351 | Methyl iodide | Not Assessed under the IRIS program. | |||||||
| 352 | Methyl isobutyl ketone (MIBK) | Not Assessed under the IRIS program. | |||||||
| 353 | Methyl isocyanate | Not Assessed under the IRIS program. | |||||||
| 354 | Methyl methacrylate | Not Assessed under the IRIS program. | |||||||
| 355 | Methyl parathion | Not Assessed under the IRIS program. | |||||||
| 356 | Methyl tert-butyl ether (MTBE) | Not Assessed under the IRIS program. | |||||||
| 357 | 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) | Not Assessed under the IRIS program. | |||||||
| 358 | 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) | Not Assessed under the IRIS program. | |||||||
| 359 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | Not Assessed under the IRIS program. | |||||||
| 360 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | Not Assessed under the IRIS program. | |||||||
| 361 | 4,4'-Methylene bis(N,N'-dimethyl)aniline | Not Assessed under the IRIS program. | |||||||
| 362 | Methylmercury (MeHg) | Not Assessed under the IRIS program. | |||||||
| 363 | 2-Methylnaphthalene | Not Assessed under the IRIS program. | |||||||
| 364 | 4-Methylphenol | Not Assessed under the IRIS program. | |||||||
| 365 | 3-Methylphenol | Not Assessed under the IRIS program. | |||||||
| 366 | 2-Methylphenol | Not Assessed under the IRIS program. | |||||||
| 367 | Metolachlor | Not Assessed under the IRIS program. | |||||||
| 368 | Metribuzin | Not Assessed under the IRIS program. | |||||||
| 369 | Mirex | Not Assessed under the IRIS program. | |||||||
| 370 | Molinate | Not Assessed under the IRIS program. | |||||||
| 371 | Molybdenum | Not Assessed under the IRIS program. | |||||||
| 372 | Monochloramine | Not Assessed under the IRIS program. | |||||||
| 373 | Naled | Not Assessed under the IRIS program. | |||||||
| 374 | Naphthalene | Not Assessed under the IRIS program. | |||||||
| 375 | Napropamide | Not Assessed under the IRIS program. | |||||||
| 376 | Nickel carbonyl | Not Assessed under the IRIS program. | |||||||
| 377 | Nickel refinery dust | Not Assessed under the IRIS program. | |||||||
| 378 | Nickel subsulfide | Not Assessed under the IRIS program. | |||||||
| 379 | Nickel, soluble salts | Not Assessed under the IRIS program. | |||||||
| 380 | Nitrapyrin | Not Assessed under the IRIS program. | |||||||
| 381 | Nitrate | Not Assessed under the IRIS program. | |||||||
| 382 | Nitric oxide | Not Assessed under the IRIS program. | |||||||
| 383 | Nitrite | Not Assessed under the IRIS program. | |||||||
| 384 | Nitrobenzene | Not Assessed under the IRIS program. | |||||||
| 385 | Nitrogen dioxide | Not Assessed under the IRIS program. | |||||||
| 386 | Nitroguanidine | Not Assessed under the IRIS program. | |||||||
| 387 | p-Nitrophenol | Not Assessed under the IRIS program. | |||||||
| 388 | 2-Nitropropane | Not Assessed under the IRIS program. | |||||||
| 389 | N-Nitroso-N-methylethylamine | Not Assessed under the IRIS program. | |||||||
| 390 | N-Nitroso-di-n-butylamine | Not Assessed under the IRIS program. | |||||||
| 391 | N-Nitrosodi-N-propylamine | Not Assessed under the IRIS program. | |||||||
| 392 | N-Nitrosodiethanolamine | Not Assessed under the IRIS program. | |||||||
| 393 | N-Nitrosodiethylamine | Not Assessed under the IRIS program. | |||||||
| 394 | N-Nitrosodimethylamine | Not Assessed under the IRIS program. | |||||||
| 395 | N-Nitrosodiphenylamine | Not Assessed under the IRIS program. | |||||||
| 396 | N-Nitrosopyrrolidine | Not Assessed under the IRIS program. | |||||||
| 397 | Nonabromodiphenyl ether | Not Assessed under the IRIS program. | |||||||
| 398 | Norflurazon | Not Assessed under the IRIS program. | |||||||
| 399 | NuStar | Not Assessed under the IRIS program. | |||||||
| 400 | Octabromodiphenyl ether | Not Assessed under the IRIS program. | |||||||
| 401 | Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) | Not Assessed under the IRIS program. | |||||||
| 402 | Oryzalin | Not Assessed under the IRIS program. | |||||||
| 403 | Oxadiazon | Not Assessed under the IRIS program. | |||||||
| 404 | Oxamyl | Not Assessed under the IRIS program. | |||||||
| 405 | Oxyfluorfen | Not Assessed under the IRIS program. | |||||||
| 406 | Paclobutrazol | Not Assessed under the IRIS program. | |||||||
| 407 | Paraquat | Not Assessed under the IRIS program. | |||||||
| 408 | Parathion | Not Assessed under the IRIS program. | |||||||
| 409 | Pendimethalin | Not Assessed under the IRIS program. | |||||||
| 410 | Pentabromodiphenyl ether | Not Assessed under the IRIS program. | |||||||
| 411 | 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) | Not Assessed under the IRIS program. | |||||||
| 412 | Pentachlorobenzene | Not Assessed under the IRIS program. | |||||||
| 413 | Pentachlorocyclopentadiene | Not Assessed under the IRIS program. | |||||||
| 414 | Pentachloronitrobenzene (PCNB) | Not Assessed under the IRIS program. | |||||||
| 415 | Pentachlorophenol | Not Assessed under the IRIS program. | |||||||
| 416 | Pentafluoroethane | Not Assessed under the IRIS program. | |||||||
| 417 | Perchlorate (ClO4) and Perchlorate Salts | Not Assessed under the IRIS program. | |||||||
| 418 | Permethrin | Not Assessed under the IRIS program. | |||||||
| 419 | Phenanthrene | Not Assessed under the IRIS program. | |||||||
| 420 | Phenmedipham | Not Assessed under the IRIS program. | |||||||
| 421 | Phenol | Not Assessed under the IRIS program. | |||||||
| 422 | m-Phenylenediamine | Not Assessed under the IRIS program. | |||||||
| 423 | Phenylmercuric acetate | Not Assessed under the IRIS program. | |||||||
| 424 | Phosalone | Not Assessed under the IRIS program. | |||||||
| 425 | Phosgene | Not Assessed under the IRIS program. | |||||||
| 426 | Phosmet | Not Assessed under the IRIS program. | |||||||
| 427 | Phosphine | Not Assessed under the IRIS program. | |||||||
| 428 | Phosphoric acid | Not Assessed under the IRIS program. | |||||||
| 429 | Phthalic anhydride | Not Assessed under the IRIS program. | |||||||
| 430 | Picloram | Not Assessed under the IRIS program. | |||||||
| 431 | Pirimiphos-methyl | Not Assessed under the IRIS program. | |||||||
| 432 | Polychlorinated biphenyls (PCBs) | Not Assessed under the IRIS program. | |||||||
| 433 | Potassium cyanide | Not Assessed under the IRIS program. | |||||||
| 434 | Potassium silver cyanide | Not Assessed under the IRIS program. | |||||||
| 435 | Prochloraz | Not Assessed under the IRIS program. | |||||||
| 436 | Prometon | Not Assessed under the IRIS program. | |||||||
| 437 | Prometryn | Not Assessed under the IRIS program. | |||||||
| 438 | Pronamide | Not Assessed under the IRIS program. | |||||||
| 439 | Propachlor | Not Assessed under the IRIS program. | |||||||
| 440 | Propanil | Not Assessed under the IRIS program. | |||||||
| 441 | Propargite | Not Assessed under the IRIS program. | |||||||
| 442 | Propargyl alcohol | Not Assessed under the IRIS program. | |||||||
| 443 | Propazine | Not Assessed under the IRIS program. | |||||||
| 444 | Propham | Not Assessed under the IRIS program. | |||||||
| 445 | Propiconazole | Not Assessed under the IRIS program. | |||||||
| 446 | beta-Propiolactone | Not Assessed under the IRIS program. | |||||||
| 447 | Propionaldehyde | Not Assessed under the IRIS program. | |||||||
| 448 | Propylene glycol | Not Assessed under the IRIS program. | |||||||
| 449 | Propylene glycol monoethyl ether | Not Assessed under the IRIS program. | |||||||
| 450 | Propylene glycol monomethyl ether (PGME) | Not Assessed under the IRIS program. | |||||||
| 451 | Propylene oxide | Not Assessed under the IRIS program. | |||||||
| 452 | Propyleneimine | Not Assessed under the IRIS program. | |||||||
| 453 | Pursuit | Not Assessed under the IRIS program. | |||||||
| 454 | Pydrin | Not Assessed under the IRIS program. | |||||||
| 455 | Pyrene | Not Assessed under the IRIS program. | |||||||
| 456 | Pyridine | Not Assessed under the IRIS program. | |||||||
| 457 | Quinalphos | Not Assessed under the IRIS program. | |||||||
| 458 | Quinoline | Not Assessed under the IRIS program. | |||||||
| 459 | Quinone | Not Assessed under the IRIS program. | |||||||
| 460 | Radium 226,228 | Not Assessed under the IRIS program. | |||||||
| 461 | Radon 222 | Not Assessed under the IRIS program. | |||||||
| 462 | Refractory ceramic fibers | Not Assessed under the IRIS program. | |||||||
| 463 | Resmethrin | Not Assessed under the IRIS program. | |||||||
| 464 | Rotenone | Not Assessed under the IRIS program. | |||||||
| 465 | Savey | Not Assessed under the IRIS program. | |||||||
| 466 | Selenious acid | Not Assessed under the IRIS program. | |||||||
| 467 | Selenium and Compounds | Not Assessed under the IRIS program. | |||||||
| 468 | Selenium sulfide | Not Assessed under the IRIS program. | |||||||
| 469 | Selenourea | Not Assessed under the IRIS program. | |||||||
| 470 | Sethoxydim | Not Assessed under the IRIS program. | |||||||
| 471 | Silver | Not Assessed under the IRIS program. | |||||||
| 472 | Silver cyanide | Not Assessed under the IRIS program. | |||||||
| 473 | Simazine | Not Assessed under the IRIS program. | |||||||
| 474 | Sodium azide | Not Assessed under the IRIS program. | |||||||
| 475 | Sodium cyanide | Not Assessed under the IRIS program. | |||||||
| 476 | Sodium diethyldithiocarbamate | Not Assessed under the IRIS program. | |||||||
| 477 | Sodium fluoroacetate | Not Assessed under the IRIS program. | |||||||
| 478 | Strontium | Not Assessed under the IRIS program. | |||||||
| 479 | Strychnine | Not Assessed under the IRIS program. | |||||||
| 480 | Styrene | Not Assessed under the IRIS program. | |||||||
| 481 | Systhane | Not Assessed under the IRIS program. | |||||||
| 482 | Tebuthiuron | Not Assessed under the IRIS program. | |||||||
| 483 | Terbacil | Not Assessed under the IRIS program. | |||||||
| 484 | Terbutryn | Not Assessed under the IRIS program. | |||||||
| 485 | Tetrabromodiphenyl ether | Not Assessed under the IRIS program. | |||||||
| 486 | 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) | Not Assessed under the IRIS program. | |||||||
| 487 | 1,2,4,5-Tetrachlorobenzene | Not Assessed under the IRIS program. | |||||||
| 488 | Tetrachlorocyclopentadiene | Not Assessed under the IRIS program. | |||||||
| 489 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin | Not Assessed under the IRIS program. | |||||||
| 490 | 1,1,1,2-Tetrachloroethane | Not Assessed under the IRIS program. | |||||||
| 491 | 1,1,2,2-Tetrachloroethane | Not Assessed under the IRIS program. | |||||||
| 492 | Tetrachloroethylene | Not Assessed under the IRIS program. | |||||||
| 493 | 2,3,4,6-Tetrachlorophenol | Not Assessed under the IRIS program. | |||||||
| 494 | Tetrachlorovinphos | Not Assessed under the IRIS program. | |||||||
| 495 | Tetraethyl lead | Not Assessed under the IRIS program. | |||||||
| 496 | Tetraethyldithiopyrophosphate | Not Assessed under the IRIS program. | |||||||
| 497 | 1,1,1,2-Tetrafluoroethane | Not Assessed under the IRIS program. | |||||||
| 498 | Tetrahydrofuran | Not Assessed under the IRIS program. | |||||||
| 499 | Thallium (I), soluble salts | Not Assessed under the IRIS program. | |||||||
| 500 | Thallium acetate | Not Assessed under the IRIS program. | |||||||
| 501 | Thallium carbonate | Not Assessed under the IRIS program. | |||||||
| 502 | Thallium chloride | Not Assessed under the IRIS program. | |||||||
| 503 | Thallium nitrate | Not Assessed under the IRIS program. | |||||||
| 504 | Thallium oxide | Not Assessed under the IRIS program. | |||||||
| 505 | Thallium selenite | Not Assessed under the IRIS program. | |||||||
| 506 | Thallium(I) sulfate | Not Assessed under the IRIS program. | |||||||
| 507 | Thiobencarb | Not Assessed under the IRIS program. | |||||||
| 508 | Thiophanate-methyl | Not Assessed under the IRIS program. | |||||||
| 509 | Thiram | Not Assessed under the IRIS program. | |||||||
| 510 | Toluene | Not Assessed under the IRIS program. | |||||||
| 511 | 2,4-/2,6-Toluene diisocyanate mixture (TDI) | Not Assessed under the IRIS program. | |||||||
| 512 | Toxaphene | Not Assessed under the IRIS program. | |||||||
| 513 | Tralomethrin | Not Assessed under the IRIS program. | |||||||
| 514 | Triallate | Not Assessed under the IRIS program. | |||||||
| 515 | Triasulfuron | Not Assessed under the IRIS program. | |||||||
| 516 | 1,2,4-Tribromobenzene | Not Assessed under the IRIS program. | |||||||
| 517 | Tribromochloromethane | Not Assessed under the IRIS program. | |||||||
| 518 | Tribromodiphenyl ether | Not Assessed under the IRIS program. | |||||||
| 519 | Tributyltin oxide (TBTO) | Not Assessed under the IRIS program. | |||||||
| 520 | 1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113) | Not Assessed under the IRIS program. | |||||||
| 521 | Trichloroacetic acid | Not Assessed under the IRIS program. | |||||||
| 522 | 1,2,4-Trichlorobenzene | Not Assessed under the IRIS program. | |||||||
| 523 | Trichlorocyclopentadiene | Not Assessed under the IRIS program. | |||||||
| 524 | 1,1,2-Trichloroethane | Not Assessed under the IRIS program. | |||||||
| 525 | 1,1,1-Trichloroethane | Not Assessed under the IRIS program. | |||||||
| 526 | Trichloroethylene | Not Assessed under the IRIS program. | |||||||
| 527 | Trichlorofluoromethane | Not Assessed under the IRIS program. | |||||||
| 528 | 2,4,5-Trichlorophenol | Not Assessed under the IRIS program. | |||||||
| 529 | 2,4,6-Trichlorophenol | Not Assessed under the IRIS program. | |||||||
| 530 | 2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) | Not Assessed under the IRIS program. | |||||||
| 531 | 2,4,5-Trichlorophenoxyacetic acid (2,4,5-T) | Not Assessed under the IRIS program. | |||||||
| 532 | 1,1,2-Trichloropropane | Not Assessed under the IRIS program. | |||||||
| 533 | 1,2,3-Trichloropropane | Not Assessed under the IRIS program. | |||||||
| 534 | Tricresol | Not Assessed under the IRIS program. | |||||||
| 535 | Tridiphane | Not Assessed under the IRIS program. | |||||||
| 536 | Triethylamine | Not Assessed under the IRIS program. | |||||||
| 537 | Triethylene glycol monobutyl ether | Not Assessed under the IRIS program. | |||||||
| 538 | Triethylene glycol monoethyl ether | Not Assessed under the IRIS program. | |||||||
| 539 | Trifluralin | Not Assessed under the IRIS program. | |||||||
| 540 | 2,2,4-Trimethylpentane | Not Assessed under the IRIS program. | |||||||
| 541 | 1,3,5-Trinitrobenzene | Not Assessed under the IRIS program. | |||||||
| 542 | 2,4,6-Trinitrotoluene (TNT) | Not Assessed under the IRIS program. | |||||||
| 543 | Uranium, natural | Not Assessed under the IRIS program. | |||||||
| 544 | Uranium, soluble salts | Not Assessed under the IRIS program. | |||||||
| 545 | Urea | Not Assessed under the IRIS program. | |||||||
| 546 | Vanadium pentoxide | Not Assessed under the IRIS program. | |||||||
| 547 | Vernam | Not Assessed under the IRIS program. | |||||||
| 548 | Vinclozolin | Not Assessed under the IRIS program. | |||||||
| 549 | Vinyl acetate | Not Assessed under the IRIS program. | |||||||
| 550 | Vinyl bromide | Not Assessed under the IRIS program. | |||||||
| 551 | Vinyl chloride | Not Assessed under the IRIS program. | |||||||
| 552 | Warfarin | Not Assessed under the IRIS program. | |||||||
| 553 | White phosphorus | Not Assessed under the IRIS program. | |||||||
| 554 | Xylenes | Not Assessed under the IRIS program. | |||||||
| 555 | Zinc and Compounds | Not Assessed under the IRIS program. | |||||||
| 556 | Zinc cyanide | Not Assessed under the IRIS program. | |||||||
| 557 | Zinc phosphide | Not Assessed under the IRIS program. | |||||||
| 558 | Zineb | Not Assessed under the IRIS program. |
References
Related files
<mfanonymousfilelist></mfanonymousfilelist>